课题基金 / 基金详情

EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA

EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA
转移性肾细胞癌中的 EGFR 抗体 225
批准号：
6303000
负责人：
FRANCISCO ROBERT
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303000
关键词：
antireceptor antibody clinical research clinical trials epidermal growth factor growth factor receptors human subject human therapy evaluation intravenous administration metastasis neoplasm /cancer chemotherapy renal cell carcinoma

项目摘要

项目成果

FRANCISCO ROBERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a phase II clinical trial using an antibody to the epidermal growth factor receptor (EGFR) in patients with metastatic renal cell carcinoma. The primary objective of the study was to determine whether the time to progression in this patient population is doubled from 4 months to 8 months following the initiation of treatment with C225 when administered biweekly intravenous infusions. Fifty-four patients were enrolled in this study (one from UAB, because of administrative issues). Time to progression for patients completing = 1 course of therapy ranges from 98 to 332 days. One partial and two minor responses were recorded. The primary side effects were grade = 3 skin toxicities manifested as follicular rash and nail had changes, which fully resolve after cessation of treatment
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
海外基金